Cardiff Oncology reports Q3 2026 results, preps Phase 3 onvansertib trial for Q1 2027Nov 16Clinical readoutBeiGeneCardiff OncologyUpdated
BeOne registers two trials: first-in-human BON-107 study and myeloma quadruplet with sonrotoclaxNov 12Weekly roundup, 2 itemsBeiGenesonrotoclax
FDA's zanubrutinib record expands with CLL/SLL approval detailNov 10Regulatory decisionBeiGenezanubrutinibUpdated
BeOne Medicines registers Phase 2 trial of BGB-B2033 in pretreated liver cancerNov 3Trial updateBeiGene
BeOne Medicines adds Phase 1 trial of BG-92505, a KEAP1 activator, in solid tumorsOct 29Weekly roundup, 3 itemsBeiGenebevacizumabUpdated
BeOne Medicines registers Phase 1 trial of BG-T0050 in DLBCL and other B-cell cancersOct 21Weekly roundup, 5 itemsazacitidineBeiGene
BeOne Medicines registers two Phase 1 hepatic impairment PK studies for sonrotoclax and tacabrutidegOct 2Weekly roundup, 2 itemsBeiGenesonrotoclax
BeOne registers Phase 3 trial of BGB-B2033 for pretreated hepatocellular carcinomaSep 23Trial updateBeiGene
BeOne Medicines registers Phase 1 drug interaction trial for CDK4 inhibitor BGB-43395Sep 15Trial updateBeiGene
Trial tests Tislelizumab plus Anlotinib as consolidation therapy in limited-stage SCLCSep 11Trial updateBeiGeneSino Biopharmaceutical
Genentech registers Phase I trial of RO7890597 in healthy volunteersSep 2Weekly roundup, 3 itemsBeiGeneobinutuzumab
BeiGene posts results for zanidatamab combo trial in HER2-positive breast, gastric cancersSep 2Trial updateBeiGenetislelizumab
BeOne Medicines files STAR Market interim report, discloses R&D spend by product under US GAAPAug 26Quarterly updateBeiGene
FDA approves Ziihera-based regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionBeiGeneJazz Pharmaceuticals
BeOne registers pediatric trial of sonrotoclax in relapsed AML and B-cell ALLAug 18Trial updateBeiGenesonrotoclax
BeOne Medicines reports Q2 2026 results, raises full-year revenue guidanceAug 5Quarterly updateBeiGenesonrotoclax
BeOne Medicines registers Phase 1a/1b trial of RAS inhibitor BG-85738 in solid tumorsAug 4Trial updateBeiGenetislelizumab
BeOne Medicines registers Phase 2 tislelizumab dosing study in Japanese ESCC patientsJul 29Trial updateBeiGenetislelizumab
BeOne Medicines-linked "High Five" Phase 3 NSCLC trial registered, not yet recruitingJul 20Trial updateBeiGenetislelizumab
BeOne Medicines registers Phase 1 bioavailability study for PRMT5 inhibitor BGB-58067Jul 17Weekly roundup, 2 itemsalcestobartBeiGene